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a  b  s  t  r  a  c  t
Heparin-induced  thrombocytopenia  (HIT)  can often  result  in  devastating  thromboembolic  outcomes.
Argatroban  is frequently  administered  as  an alternative  anticoagulant  to heparin.  We  present  a  compli-
cated  case  of  HIT in which  off-pump  coronary  artery  bypass  grafting  was  performed  using anticoagulation
with  argatroban.  Although  the  active  clotting  time  was  maintained  between  220  and  270  s  usingeywords:
rgatroban
ff-pump coronary artery bypass
eparin-induced thrombocytopenia
argatroban,  intraoperative  thrombotic  complications  and  postoperative  prolonged  coagulopathy  were
encountered.
<Learning  objective:  The  use  of argatroban  involves  a potential  risk  of  inadequate  anticoagulation  or  life-
threatening  postoperative  bleeding  depending  on  the  dose.  We  recommend  that  the  target  ACT  during  off-
pump  coronary  artery  bypass  grafting  with  argatroban  should  be  strictly  maintained  over 250 s,  although
an  ACT exceeding  300  s may  cause  prolonged  coagulopathy>.
©  2ntroduction
Heparin-induced thrombocytopenia (HIT) often results in
evastating thromboembolic outcomes. The synthetic thrombin
nhibitor, argatroban, has been administered as an alternative
nticoagulant to heparin in standard cardiac surgery [1–4]. Car-
iopulmonary bypass under the administration of argatroban is
till controversial and includes a lot of risk, although the mini-
um  dose to increase the active clotting time (ACT) over 400 s is
ecommended in the regimen for open cardiac surgery using car-
iopulmonary bypass [2]. On the other hand, the regimen for the
ose in off-pump coronary artery bypass grafting (OPCAB) has not
een established. We  present a complicated case of HIT in which
PCAB was performed using anticoagulation with argatroban.
ase report
A 55-year-old man  presented to our hospital with dyspnea and
ack pain caused by unstable angina. One year before presentation,
emodialysis had been introduced because of diabetic nephropa-
hy; at this time, he was  ﬁrst shown to have HIT type II. Since the
iagnosis, argatroban has been used as an alternative anticoagulant
herapeutic agent during hemodialysis. On admission, the patient’s
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creatinine phosphokinase level had mildly elevated to 277 U/L.
Echocardiogram revealed diffuse hypokinesis of the left ventri-
cle, and the ejection fraction was  estimated to be 38%. Coronary
angiogram showed 90% stenosis of the left main trunk with 2-vessel
coronary artery disease. The platelet count was 127 000 mm–3.
An urgent operation was scheduled because of unstable hemo-
dynamics, and an intraaortic balloon pump (IABP) was inserted
prophylactically prior to the operation.
The baseline ACT was  150 s at surgery. Argatroban (0.3 mg/kg)
was administered intravenously with a bolus injection before
OPCAB, and a continuous drip infusion at the rate of 5 g/kg/min
was added in accordance with the protocol described previously
[1]. The ACT was  measured every 15 min and was  maintained at
over 200 s (Fig. 1). In addition, the activated partial thromboplas-
tin time (APTT) was  prolonged to more than 2.5 times that of the
normal value. There was no discrepancy between ACT and APTT
level. OPCAB was  performed by anastomosis of the left internal
mammary artery to the left anterior descending artery and the
saphenous vein to the diagonal branch and the right coronary
artery. Fresh clots were found in the vein graft and the pericardium
cavity when approaching the proximal anastomosis of the saphe-
nous vein using a suture device. The ACT at that time was  217 s;
therefore, the dose of argatroban was increased to achieve and
maintain the ACT at more than 250 s. The clot was  removed from
the vein graft and all of the anastomoses were completed. Fortun-
ately, ischemic change or hemodynamic instability did not occur
during the surgery. Argatroban was discontinued at the end of
llege of Cardiology.
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[ig. 1. Dose effect of argatroban (Arg) on the activated clotting time (ACT) or the
ctivated partial thromboplastin time (APTT) during and after surgery. FFP, ﬂesh
rozen plasma.
urgery. However, postoperative measurements revealed that the
CT had been over 250 s for 4 h, after which it slowly decreased.
he patient was given fresh frozen plasma and platelets and the
CT ﬁnally returned to normal after 12 h. Although the amount
f bleeding from the chest drain was 900 ml  in 6 h, bleeding was
educed concurrent with ACT normalization. The postoperative
ourse was uneventful and the patient was discharged without any
omplications in 2 weeks. Postoperative multidetector computed
omography revealed that all bypass grafts were patent.
iscussion
The frequency of HIT has been reported as 1.0–2.4% in adult
atients undergoing cardiac surgery [5]. Urgent OPCAB was
equired for limited unstable angina in our patient because of his
eteriorating hemodynamics. However, our patient had a history of
IT-antibody positivity and, unfortunately, it would have taken at
east 1 week to determine whether it was still positive. Therefore,
rgatroban was used as an alternative anticoagulant to heparin. An
ABP was also inserted for more secure OPCAP, which allowed us
o reduce the dose of argatroban, by avoiding the use of cardiopul-
onary bypass.
Argatroban is a direct thrombin inhibitor and has several advan-
ages because it is nonantigenic, has a short half-life of 39–53 min,
ndergoes natural hepatobiliary excretion, is not dependent on
enal function, and is concentration-dependent [6]. However,
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a disadvantage of this agent is that there are no argatroban-
neutralizing agents. Although the successful use of argatroban
during cardiac surgery has been reported [1,2], safe and effective
doses of argatroban have not been established through clinical trials
[5]. In several cases, ACT was  not prolonged with a recommended
argatroban protocol [7]. Failed anticoagulation occurred even with
an ACT between 230 and 270 s during OPCAB, as shown in a case
report [8].
On the other hand, argatroban can result in severe coagu-
lopathy [4]. In our case, the ACT was maintained between 220
and 260 s. Although no major bleeding complications occurred, an
extended period was required to normalize the ACT after OPCAB.
Postoperative liver function was  grossly normal, and major causes
of prolonged coagulopathy such as signiﬁcant thrombocytopenia
or hypoﬁbrinogenemia and perioperative hypothermia were not
observed. Therefore, argatroban itself may  have been involved in
prolonged coagulopathy [4]. Otherwise, the ACT may  not be ade-
quate for monitoring of anticoagulation with the use of argatroban
[8].
In conclusion, argatroban has no neutralizing agents, and the
use of argatroban involves a potential risk of inadequate antico-
agulation or life-threatening postoperative bleeding depending on
the dose. In our practice, argatroban was started with a bolus dose
0.3 mg/kg followed by an infusion of 6–8 g/kg/min. We  recom-
mend that the target ACT during OPCAB with argatroban should
be strictly maintained over 250 s, although an ACT exceeding 300 s
may  cause prolonged coagulopathy.
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